Literature DB >> 11208927

Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

S Przedborski1, Q Chen, M Vila, B I Giasson, R Djaldatti, S Vukosavic, J M Souza, V Jackson-Lewis, V M Lee, H Ischiropoulos.   

Abstract

Structural and functional alterations of alpha-synuclein is a presumed culprit in the demise of dopaminergic neurons in Parkinson's disease (PD). Alpha-synuclein mutations are found in familial but not in sporadic PD, raising the hypothesis that effects similar to those of familial PD-linked alpha-synuclein mutations may be achieved by oxidative post-translational modifications. Here, we show that wild-type alpha-synuclein is a selective target for nitration following peroxynitrite exposure of stably transfected HEK293 cells. Nitration of alpha-synuclein also occurs in the mouse striatum and ventral midbrain following administration of the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Conversely, beta-synuclein and synaptophysin were not nitrated in MPTP-intoxicated mice. Our data demonstrate that alpha-synuclein is a target for tyrosine nitration, which, by disrupting its biophysical properties, may be relevant to the putative role of alpha-synuclein in the neurodegeneration associated with MPTP toxicity and with PD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208927     DOI: 10.1046/j.1471-4159.2001.00174.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  48 in total

Review 1.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Du-Chu Wu; Peter Teismann; Kim Tieu; Miquel Vila; Vernice Jackson-Lewis; Harry Ischiropoulos; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

3.  Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.

Authors:  Ashley D Reynolds; David K Stone; Jessica A L Hutter; Eric J Benner; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2010-01-29       Impact factor: 5.422

4.  Pre-clinical therapeutic development of a series of metalloporphyrins for Parkinson's disease.

Authors:  Li-Ping Liang; Jie Huang; Ruth Fulton; Jennifer N Pearson-Smith; Brian J Day; Manisha Patel
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-08       Impact factor: 4.219

Review 5.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

6.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

Review 7.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 9.  Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics.

Authors:  Desmond J Smith
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.